\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes HealthThe results of the evaluation are:
Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs - HORIZON-HLTH-2022-DISEASE-06-02-two-stage
Vaccines 2.0 - developing the next generation of vaccines - HORIZON-HLTH-2022-DISEASE-06-03-two-stage
Development of new effective therapies for rare diseases - HORIZON-HLTH-2022-DISEASE-06-04-two-stage
In accordance with General Annex D of the Work Programme, the evaluation of the first-stage proposals was made looking only at the criteria 'excellence' and 'impact'. The threshold for both individual criteria is 4. The overall threshold applying to the sum of the two individual scores was set at a level that ensures the total requested budget of proposals admitted to stage 2 is as close as possible to three times the available budget, and not less than two and a half times the available budget, and is as follows:
Source: Funding & Tenders Portal (Funding Updates)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
